Palvella's Phase III Success And Fast Track Status Test Current Valuation [Yahoo! Finance]
Palvella Therapeutics, Inc. (PVLA)
Company Research
Source: Yahoo! Finance
Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Palvella Therapeutics (NasdaqCM:PVLA) reported positive Phase III results for its lead therapy targeting a rare disease with significant unmet medical need. The company secured substantial new financing and expanded its rare disease pipeline with additional candidates. Palvella received FDA Fast-Track designation for its lead program, supporting a potentially accelerated review process. The company appointed a new Senior Vice President of Market Access and Patient Services to prepare for potential commercialization. Palvella Therapeutics enters this news cycle with its shares at $120.38 and a 1-year return of about 3.5x, while year-to-date performance is up 20.0%. That backdrop indicates that investors have already been reacting to earlier milestones, making these new updates important context for anyone tracking rare disease companies. The combination of late-stage clinical progress,
Show less
Read more
Impact Snapshot
Event Time:
PVLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PVLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PVLA alerts
High impacting Palvella Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PVLA
News
- Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of DirectorsGlobeNewswire
- Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of SalesGlobeNewswire
- Palvella Therapeutics (PVLA) had its price target raised by Chardan Capital from $210.00 to $240.00. They now have a "buy" rating on the stock.MarketBeat
- Palvella Therapeutics Inc (PVLA) Q4 2025 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]Yahoo! Finance
- Palvella Therapeutics GAAP EPS of -$3.71 misses by $0.19 [Seeking Alpha]Seeking Alpha
PVLA
Earnings
- 3/31/26 - Miss
PVLA
Sec Filings
- 4/17/26 - Form 4
- 4/15/26 - Form 4
- 4/15/26 - Form 3
- PVLA's page on the SEC website